Androgenic deprivation therapy in prostate cancer as metabolic syndrome cause and coronary artery disease risk factor

• Grant number: 11/07620-9
• Support Opportunities: Regular Research Grants
• Start date: August 01, 2013
• End date: July 31, 2016
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: Carlos Vicente Serrano Junior
• Grantee: Carlos Vicente Serrano Junior
• Host Institution: Instituto do Coração Professor Euryclides de Jesus Zerbini (INCOR). Hospital das Clínicas da Faculdade de Medicina da USP (HCFMUSP). Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil
• Associated researchers: Cesar da Camara Segre ; Fernando Vissoci Reiche

Abstract

The prostate cancer, excluding skin malignant disease, shows the higher incidence among all types of cancer in male. There is a progressive increase in its incidence in Brazil, partly justified by evolution in diagnosis methods, better information systems and enlargment of survival. Nearly 86% of the prostate cancer diagnosis are made when the disease still localized and cure reaches 98.8%. Androgenic deprivation therapy is a treatment option since 1941 and your indications were expanded in the last years. Nevertheless, the androgen supression may induce body composition alterations, variation in insulin and glucose blood levels, dyslipidemia, hypertension and metabolic syndrome, all risk factors for coronary arterial disease.The present studt intends to evaluate the androgen deprivation therapy in prostate cancer patients sa cause of metabolic syndrome and risk factor for coronary arterial disease, besides set the inflamatory, endothelial and trombotic profiles for cardiovascular disease in patients with prostate cancer and clinic indication of androgen supression, by drugs or cirurgical procedure.This coorte will evaluate patients od the Urology division of "Hospital das Clínicas" of Medical school of São Paulo university and indication of androgen deprivation therapy as type of treatment for the disease stage.The present study pretends to evaluate with gruop of patients with prostate cancer have the higher metabolic changes, and therefore, benefits of preventive strategies for cardiovascular disease. (AU)